[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552940":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":49,"collaborators":20,"id":51,"slug":20,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":20,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":20,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Children's Hospital of Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"long term follow up","EXPERIMENTAL","All participants who complete CS-101-03(NCT0606518) studie after CS-101 infusion will be asked to participate in this long-term follow-up study.",[13],"Genetic: CS-101",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"GENETIC","CS-101","Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Xiaowen Zhai, M.D.","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+86-021-64931126","zhaixiaowendy@163.com",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Zifeng Li, M.S.","+86-13920704768","zfli18@fudan.edu.cn",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Shanghai","Shanghai Municipality","201102","China",{"type":42,"coordinates":43},"Point",[44,45],121.45806,31.22222,{"lat":45,"lon":44},[48],{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},{"type":50,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100552940",false,"NCT06479616","A Long-term Follow-up Study in Participants Who Received CS-101","A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With Base-edited Autologous Hematopoietic Stem Cell (CS-101) Transplantation","Inclusion Criteria:\n\n* Participants (or his or her legally appointed and authorized representative or guardian) must sign and date informed consent form (ICF) and, where applicable, an assent form\n* Participants must have received CS-101 infusion in last IIT study\n\nExclusion Criteria:\n\n* There are no exclusion criteria","ALL","3 Years","17 Years",{"count":61,"type":62},5,"ESTIMATED","INTERVENTIONAL",[65],"NA","This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-03 (NCT06065189)",[68],"Beta-Thalassemia","2025-09-04",{"date":71,"type":72},"2025-09-10","ACTUAL",{"date":74,"type":72},"2024-06-18",{"date":76,"type":62},"2027-06",{"name":5,"class":6},1]